Treatment and Survival Continuation Study of Atamestane Plus Toremifene vs Letrozole in Advanced Breast Cancer
Open Label Treatment and Survival Continuation Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer
Sponsor: Intarcia Therapeutics
Terminated
This was a follow-on study to Biomed 777-CLP-029 which did not meet superiority endpoint
Other terminated trials from Intarcia Therapeutics
Other Breast Neoplasms trials with similar outcome
A PHASE3 clinical study on Breast Neoplasms and Neoplasms, Hormone-Dependent, this trial is terminated or withdrawn. The trial is conducted by Intarcia Therapeutics and has accumulated 6 data snapshots since 2005. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE3
First recorded
Nov 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Intarcia Therapeutics
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Arkhangelsk, Russia , Dnipro, Ukraine , Donetsk, Ukraine , Greenbrae, United States , Houston, United States , Ivano-Frankivsk, Ukraine , Kansas City, United States , Kazan', Russia , Kharkiv, Ukraine , Kiev, Ukraine and 25 more locations